The global race to sell weight-loss drugs has created an unusual marketing problem for pharmaceutical companies: demand for the products is immense, but in most countries the companies that make them are barred from advertising prescription medicines directly to the public.

That tension is especially visible in Britain, where Novo Nordisk and Eli Lilly are competing for patients, prescribers and market share while navigating rules that prohibit advertising prescription-only medicines to consumers.

The companies can discuss obesity, sponsor public-information campaigns and promote their corporate brands.

They cannot directly tell the public to ask for a named prescription drug.

Novo Nordisk, the Danish maker of Ozempic and Wegovy, recently staged a public exhibition in London built around the experience of living with obesity.

The campaign described obesity as a complex chronic condition and encouraged people to seek informed medical conversations.

Novo Nordisk's name was visible, but its products were not promoted.

That is the defining distinction in markets with strict pharmaceutical-advertising rules.

A disease-awareness campaign may inform the public about symptoms, risks and treatment pathways, but it must not become an indirect advertisement for a specific prescription medicine.

The boundary is often difficult to draw, particularly when a company is strongly associated with a small number of highly recognisable products.

Ozempic and Wegovy contain semaglutide, a drug in the glucagon-like peptide-one, or GLP-one, class.

Ozempic is authorised for type two diabetes, while Wegovy is authorised for weight management in eligible patients.

Eli Lilly's Mounjaro and Zepbound contain tirzepatide and are used, under different authorisations, for diabetes treatment and weight management.

Access, suitability and prescribing rules differ by country and should be decided by a qualified clinician.

The United States is an outlier in allowing direct-to-consumer advertising of prescription medicines, alongside New Zealand.

American viewers regularly see advertising for medicines on television, online and social media, including campaigns for obesity and diabetes treatments.

In Britain, France and most other countries, that type of consumer advertising is prohibited.

The contrast has become commercially important as GLP-one medicines reshape the pharmaceutical market.

The treatments can produce substantial weight loss for some patients, but they are not interchangeable, are not suitable for everyone and can cause side effects.

Their popularity has also generated intense pressure on supply, pricing, telehealth services and regulators responsible for preventing misleading medical claims.

Eli Lilly has run a UK campaign stating that obesity is a complex disease and directing people to an online questionnaire intended to support a discussion with a healthcare professional.

The Advertising Standards Authority has received more than 100 complaints about the campaign, an unusually high number for a single advertisement.

Some complainants argued that Lilly had not made its commercial interest sufficiently clear.

The regulator is assessing those complaints and has not decided whether to open a formal investigation.

That distinction matters: complaints are not findings of a breach, and the campaign remains subject to assessment under rules governing prescription-medicine promotion and advertising transparency.

France has taken a tougher line.

The French medicines regulator, the National Agency for the Safety of Medicines and Health Products, fined Novo Nordisk France about €1.78 million and Eli Lilly France about €108,766 over campaigns it concluded amounted to indirect promotion of prescription-only obesity medicines.

The agency said the campaigns could mislead people in a climate of intense media attention and increasing misuse of GLP-one drugs for aesthetic weight loss.

Novo Nordisk has said it is exploring legal options to challenge the French decision and maintains that its campaigns were disease-awareness and prevention work intended to support safe patient care.

Eli Lilly has said its French communication was consistent with the applicable framework.

The penalties do not establish wrongdoing in other countries, but they illustrate how closely regulators are scrutinising campaigns that stop short of naming a medicine while promoting awareness of the condition it treats.

The commercial rivalry has now reached the courts in the United States.

Novo Nordisk filed a lawsuit in New Jersey accusing Eli Lilly of false and misleading advertising for Mounjaro and Zepbound.

Novo alleges that Lilly used outdated comparative data that made Lilly's drugs appear more effective than the currently available versions of Wegovy and Ozempic.

Eli Lilly rejects that allegation and says its advertising relies on robust clinical data from a head-to-head trial.

The lawsuit has not been decided.

It is part of a broader contest between the two companies over how efficacy, dosing, safety and clinical evidence are presented to patients and healthcare professionals.

The most aggressive promotion is not always coming from the manufacturers.

Online pharmacies and telehealth businesses have built fast-growing weight-loss services around prescription medicines, often using before-and-after imagery, subscription offers and language that can blur the line between promoting a healthcare service and advertising a particular drug.

British advertising regulators have warned that some online sellers operate in a grey area by using visual cues or pricing structures that strongly imply a prescription medicine without naming it.

The concern is not merely legal.

Promotional material can encourage inappropriate use, obscure medical risks or lead consumers to assume that a drug is available without an individual clinical assessment.

US regulators are also tightening enforcement against the marketing of compounded versions of GLP-one medicines.

The Food and Drug Administration has issued warning letters to telehealth companies over claims that it said were false or misleading, including suggestions that compounded products were approved by the agency or equivalent to branded medicines.

Compounded medicines are not approved by the Food and Drug Administration in the same way as branded products.

They are individually prepared formulations that may be used in specific circumstances, rather than mass-produced approved drugs.

Their rapid growth during shortages of branded GLP-one medicines made clear how quickly commercial demand could outrun public understanding of the difference.

The advertising dispute is therefore about more than slogans and billboards.

It concerns who shapes public demand for powerful prescription medicines, how accurately the benefits and risks are explained, and whether disease-awareness campaigns help patients seek appropriate care or become a disguised route to commercial promotion.

For Novo Nordisk, Eli Lilly, online pharmacies and regulators, the next phase will be defined by enforcement decisions, court rulings and the continuing effort to distinguish legitimate health information from advertising designed to drive demand for a specific prescription product.

Taiwanese President Lai Ching-te has taken part in a wartime command-continuity drill during the island's largest annual military exercises, travelling by armoured personnel carrier from the Presidential Office in Taipei to a protected command centre as part of preparations for a possible Chinese attack.

The late-night exercise, known as the Wan Chun drill, simulated the protection and relocation of Taiwan's president and senior officials during an emergency in which the leadership or the capital's command structure came under threat.

Lai was filmed wearing body armour and a helmet, receiving military briefings and issuing instructions after reaching the command location.

The purpose was not an evacuation from Taiwan or a rehearsal for the collapse of government.

It was a continuity-of-government exercise intended to ensure that the president, military leadership and civilian agencies could continue to make decisions if normal communications, transport routes or government buildings were disrupted.

Taiwan's Presidential Office said the drill examined command arrangements, inter-agency co-ordination and emergency-response mechanisms needed to keep the government functioning.

The exercise formed part of the 10-day Han Kuang military drills, Taiwan's annual test of its ability to respond to an invasion, blockade or other major conflict.

This year's exercise began on 5 August and is scheduled to run until 14 August.

It combines live military activity, reserve mobilisation, civil-defence preparation and tests of how the country would cope if communications and critical infrastructure were damaged.

Lai is the first known incumbent president to take part publicly in the Wan Chun exercise, although earlier Taiwanese leaders also rehearsed emergency relocation and command procedures.

The programme dates to the Cold War period and reflects a longstanding concern that an adversary might try to disable Taiwan's political and military leadership early in a conflict.

Such an operation is commonly described as a decapitation strike: an attack intended to remove or isolate senior leaders, disrupt communications and paralyse decision-making before a defending force can organise a response.

Taiwan's drill assumes that defending the island would depend not only on aircraft, ships and missiles, but also on the ability of national institutions to keep operating under pressure.

The scenario has added urgency because China has never renounced the use of force to bring Taiwan under its control.

Beijing claims the self-governed island as part of its territory despite never having governed it, while Taipei rejects that claim and says its future can be decided only by its people.

China's military has increased operations around Taiwan, including air and naval activity, coastguard patrols and other forms of pressure that fall below the threshold of open war.

These so-called grey-zone activities are a central focus of this year's Han Kuang exercise.

They can include maritime harassment, cyber operations, disinformation, administrative pressure and the use of non-military or quasi-military forces to test an opponent's readiness without formally launching an invasion.

Taiwan is using the drills to test how quickly its armed forces and civilian institutions can respond when the first warning of a crisis is unclear or fragmented.

The exercise has also shifted beyond conventional displays of weaponry.

Taiwan has mobilised large numbers of reservists to practise protecting ports, power facilities, bridges and other infrastructure that would be essential in a prolonged conflict.

Air-defence systems, including Patriot and Tien Kung missiles, have been deployed in and around Taipei, while troops have practised the defence of transport routes and urban approaches to the capital.

One prominent exercise focused on the recently opened Danjiang Bridge across the Tamsui River northwest of Taipei.

The bridge and surrounding river corridor could be strategically important in a conflict because the area links coastal approaches, transport networks and routes towards the capital.

Soldiers erected barriers and barbed wire to simulate delaying or blocking an opposing force's advance.

Taiwan is also testing whether its military can operate with more decentralised command.

The drills include a communication method known as backbriefing, in which junior commanders explain how they intend to carry out orders rather than simply acknowledge them.

The approach is designed to help front-line units act more independently if senior headquarters are cut off, communications fail or battlefield conditions change quickly.

For the first time, the authorities also plan to limit mobile internet capacity during part of the exercise.

The test is intended to show how government agencies, businesses and the public would communicate if bandwidth became scarce during a cyberattack, disaster or military emergency.

The measure reflects a broader recognition that Taiwan's resilience would depend on civilian communications, supply chains, emergency services and public preparedness as much as on military firepower.

The Han Kuang exercise comes as Taiwan expands defence spending and seeks to turn its military into a force better prepared for an asymmetric conflict against a far larger adversary.

That means concentrating on mobile missiles, drones, mines, air defence, coastal protection, reserve forces and the ability to survive an initial attack rather than relying solely on expensive conventional platforms.

Taiwan's security planning is closely watched in Washington, Tokyo and other Indo-Pacific capitals because a conflict across the Taiwan Strait would threaten one of the world's most important shipping lanes and place the global semiconductor supply chain at risk.

Taiwan produces a dominant share of the world's advanced chips, making the island's security a strategic economic issue as well as a military one.

The United States remains Taiwan's principal supplier of military equipment, while maintaining formal diplomatic recognition of Beijing rather than Taipei.

Washington's policy leaves open how it would respond in a war, but it treats peace and stability in the Taiwan Strait as a matter of major concern.

Taiwan has drawn on American training practices and doctrine as it reshapes its own forces, although its defence ultimately rests on its ability to sustain operations from the first hours of a crisis.

The Wan Chun drill therefore carried a message beyond the armoured convoy seen in Taipei.

It was a test of whether Taiwan's leadership can remain protected, connected and capable of directing national defence if the country faces the kind of sudden, multi-layered attack its military believes is increasingly plausible.

The remaining days of the Han Kuang exercise will continue to test that wider system of military resistance and civilian resilience.

A lightning strike killed Yala FC player Safwan Awae during a football match in southern Thailand, injuring 12 other players and forcing the abandonment of a regional cup fixture in Narathiwat province.

Awae, 24, was struck when lightning hit the pitch at Santiphap Stadium in Su-ngai Kolok on 4 August.

The Golok FA Cup match was being played amid heavy rain, strong winds and thunderstorms when a sudden bolt sent a flash across the field.

The player, whose name was initially reported in some accounts as Suphan Awae, was Safwan Awae.

He received emergency treatment at the stadium and was taken to hospital, where he died from his injuries.

Police said 12 others were injured, including Malaysian player Mohamad Alif Ezzahan Zulkifli, 22. Players suffered burns and other effects of the electrical discharge, and several required hospital monitoring.

Local reports varied over the number of people who remained in hospital after the incident.

The match was a Golok FA Cup semi-final, not a friendly.

The tournament features local teams from Thailand’s southern border provinces and teams from Malaysia.

Awae had recently signed for Yala FC, a Thai League 3 club, after previously playing for Pattani FC.

Yala FC expressed condolences to his family, describing him as a new player of the club.

The death has renewed concern about suspending outdoor sporting events when thunderstorms are active, particularly during Thailand’s rainy season.